• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,104
103
69
68
65

COUNTRY

63
19
16
10
9

CATEGORIES

  • 89
  • 128
  • 71
  • 72
  • 44
  • 43
  • 21
  • 16
  • 20
  • 22

PRICE

547
805
1,609
2,607

PUBLISHED

237
293
747
2,607

PRODUCT TYPE

2,460
72
61
12
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Triple Analysis: Leukemia, Melanoma and Apoptosis Triple Analysis: Leukemia, Melanoma and Apoptosis - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Apoptosis

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Lung Cancer, Lymphoma and Melanoma Triple Analysis: Lung Cancer, Lymphoma and Melanoma - Product Thumbnail Image

Triple Analysis: Lung Cancer, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Lung Cancer, Melanoma and Antibodies Triple Analysis: Lung Cancer, Melanoma and Antibodies - Product Thumbnail Image

Triple Analysis: Lung Cancer, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Lymphoma, Melanoma and Antibodies Triple Analysis: Lymphoma, Melanoma and Antibodies - Product Thumbnail Image

Triple Analysis: Lymphoma, Melanoma and Antibodies

This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Protein Kinase Inhibitors Triple Analysis: Melanoma, Pancreatic Cancer and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Angiogenesis and Peptides Triple Analysis: Melanoma, Angiogenesis and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Angiogenesis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides)....

June 2013
FROM
Triple Analysis: Leukemia, Lymphoma and Melanoma Triple Analysis: Leukemia, Lymphoma and Melanoma - Product Thumbnail Image

Triple Analysis: Leukemia, Lymphoma and Melanoma

This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five...

June 2013
FROM
Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Leukemia, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Leukemia, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Melanoma, Pancreatic Cancer and Peptides Triple Analysis: Melanoma, Pancreatic Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Pancreatic Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Apoptosis and Peptides Triple Analysis: Melanoma, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

June 2013
FROM
Triple Analysis: Breast Cancer, Lung Cancer and Melanoma Triple Analysis: Breast Cancer, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Peptides Triple Analysis: Melanoma, Prostate Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Melanoma, Apoptosis and Angiogenesis Triple Analysis: Melanoma, Apoptosis and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Angiogenesis

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific...

June 2013
FROM
Triple Analysis: Melanoma, Antibodies and Peptides Triple Analysis: Melanoma, Antibodies and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Antibodies and Peptides

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos